Introduction
Over the last years, there have been relevant advances in cancer research and in treatment based on specific genetic alterations improving survival in some tumors. Nevertheless, progress is still dismal in most carcinomas when are disseminated with metastasis; the survival is less than 30% in most cases. Then, we need to move forward looking for new paradigms which may explain the complex mechanisms involved in carcinogenesis and in new treatment approaches.
With these objectives, we met this month of July, in the Aragonian Pyrenees, a group of 15 scientists conducting research in Spain who are changing many paradigms in research and developing disruptive projects. In a 3-day meeting, we share ideas and establish an ideal framework of collaborations, where pathologists, oncologists, biologists, bioinformaticians and data scientists, altogether, looked for new approaches and synergistic teams. Most researchers are younger than 45 years, and their outstanding findings and talent made us to be optimistic for great advances in upcoming years. This was the first one of a series of summer meetings that we are planning to organize. Other 15-20 more younger outstanding researchers will be invited to participate in the forthcoming editions.
Some of the most relevant highlights of the meeting can be summarized in the following points:
The proposal of new paradigms in cancer research (a Alejo Efeyan emphasized that reprogrammed metabolism is a hallmark of tumor cells, as most mutations selected in cancer increase nutrient uptake, fuel anabolism, and even have a negative effect on the metabolism of the patient. Fortunately, the energetic demands associated with oncogenic mutations constitute a potential vulnerability that many laboratories are trying enumerate and understand, to then exploit therapeutically. In particular, Dr. Efeyan pinpointed vulnerabilities of follicular lymphomas caused by activating mutations in the nutrient signaling cascade upstream of the mTOR kinase, a master regulator of anabolism. Dr. Efeyan described the selective sensitivity of this group of tumors to pharmacological inhibition of mTOR using genetically engineered mice. (c) The new approaches of inflammation and cancer by Dr.
Julián Pardo, and Dr. María Abad, who contributed in presentation data that support the relationship between inflammation and the development of some tumors, as well as plasticity and change of cellular phenotype. The most recent experimental and clinical data suggest that the relationship between inflammation and cancer is not restricted to the initiation of the carcinogenic process but, in addition, the composition of the inflammatory microenvironment affects the outcome of anticancer therapy, including traditional treatments like chemotherapy or radiotherapy as well as the most recent advances in biologicals and immunotherapies. On this basis, Dr. Pardo reviewed the new possibilities of selectively modulating the inflammatory immune response to prevent the development of cancer or to treat it, minimizing possible side effects. 
The presentation of new approaches in cancer treatment
(a) Based on new genetic targets, as the so-called master genes. The outstanding work of Dr. Laura Soucek, who has developed the first inhibitor against the Myc transcription factor based on a cell-penetrating peptide (Omomyc) with dominant negative action and that is already in clinical development. The Omomyc-purified mini-protein behaves as a cell-penetrating peptide and could be used as a drug. This novel and unexpected feature allowed us to treat non-small cell lung cancer (NSCLC) in vitro and in vivo, showing significant efficacy and an excellent safety profile. Finally, thanks to an ongoing effort for more than 20 years, Omomyc will reach clinical trials in 2020 for NSCLC and breast cancer, and, if proven effective, could be applied to many more oncological indications. (b) The presentation of a novel antitumor agent, Trabectidin, of marine origin, Dr. José Jimeno. Presented how Trabectidin, a marine-derived anticancer drug can be developed through the fusion of clinical evidence and molecular biology: the model leads to the identification of soft tissue sarcoma patients, specifically round cell mixed liposarcoma bearing the t 12;16 that lead to the CHOP FUS fusion gene: a 90% rate of long lasting responses and tumor control can be achieved, moreover, if type III translocations are excluded, the model of therapeutic intervention in this patients with Trabectidin achieves a 100% rate of tumor control including responses lasting for more than 2 years. In summary, new paradigms and disruptive projects are coming with promising perspectives. We ask for greater investment in science strengthening networks and research teams promoting disruptive investigations which are almost never financed by the state agencies. Proposal can be favoring fiscally the private donations that can help the works based on new paradigms and that State agencies support with about 20% its budget to disruptive ideas of researchers as most successful technological companies do.
